540737-29-9 | 2-hydroxypropane-1,2,3-tricarboxylic acid; 3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$15.00	$10.00
50mg	97%	in stock	$26.00	$18.00
100mg	97%	in stock	$32.00	$22.00
250mg	97%	in stock	$49.00	$34.00
1g	97%	in stock	$89.00	$63.00
5g	97%	in stock	$331.00	$232.00
10g	97%	in stock	$572.00	$400.00
25g	97%	in stock	$1,131.00	$792.00
100g	97%	in stock	$3,401.00	$2,381.00

Description

• Catalog Number: AG24320
• Chemical Name: 2-hydroxypropane-1,2,3-tricarboxylic acid; 3-[(3R,4R)-4-methyl-3-[methyl({7H-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile
• CAS Number: 540737-29-9
• Molecular Formula: C22H28N6O8
• Molecular Weight: 504.4931
• MDL Number: MFCD11616529
• SMILES: OC(=O)C(CC(=O)O)(CC(=O)O)O.N#CCC(=O)N1CC[C@H]([C@H](C1)N(c1ncnc2c1cc[nH]2)C)C

Computed Properties

• Complexity: 716
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 12
• Hydrogen Bond Donor Count: 5
• Rotatable Bond Count: 8

Literature

• Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.

  Journal of Crohn's & colitis 20180101

• Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.

  Gut 20170601

• Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.

  The New England journal of medicine 20170504

• Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.

  Arthritis & rheumatology (Hoboken, N.J.) 20170101

• Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20170101

• Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).

  Future medicinal chemistry 20160901

• Tofacitinib for the treatment of psoriasis.

  Expert opinion on pharmacotherapy 20160701

• Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.

  Rheumatology (Oxford, England) 20160601

• Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.

  Journal of the American Academy of Dermatology 20160501

• Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.

  The Journal of allergy and clinical immunology 20160401

• Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

  Blood 20160310

• Elucidating the Mechanism of Tofacitinib Oxidative Decyanation.

  Drug metabolism letters 20160101

• Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.

  Clinical and experimental rheumatology 20160101

• Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.

  European journal of pharmacology 20151015

• Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).

  Journal of clinical immunology 20151001

• Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.

  Oncotarget 20150821

• Effects of tofacitinib on nucleic acid metabolism in human articular chondrocytes.

  Modern rheumatology 20150701

• The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.

  Annals of the rheumatic diseases 20150601

• Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.

  Leukemia 20150401

• White-to-brown metabolic conversion of human adipocytes by JAK inhibition.

  Nature cell biology 20150101

• Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.

  Arthritis research & therapy 20150101

• Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.

  The Journal of investigative dermatology 20141201

• Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.

  Journal of medicinal chemistry 20140626

• Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib.

  The Journal of investigative dermatology 20140401

• Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.

  Antimicrobial agents and chemotherapy 20140401

• JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

  Leukemia 20140201

• Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity.

  Cornea 20140201

• IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages.

  Journal of immunology (Baltimore, Md. : 1950) 20140101

• JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.

  Journal of immunology research 20140101

• Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma.

  Toxicology and applied pharmacology 20131215

• Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.

  Clinical and experimental immunology 20131201

• Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease.

  Journal of clinical immunology 20130401

• Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.

  Arthritis and rheumatism 20121201

• JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.

  Arthritis and rheumatism 20121101

• Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20120901

• Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

  The British journal of dermatology 20120901

• Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

  The New England journal of medicine 20120816

• Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

  The New England journal of medicine 20120809

• Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

  The New England journal of medicine 20120809

• [Janus kinase inhibitors].

  Zeitschrift fur Rheumatologie 20120801

• Tofacitinib for the treatment of moderate to severe rheumatoid arthritis.

  Drugs of today (Barcelona, Spain : 1998) 20120801

• Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.

  British journal of clinical pharmacology 20120701

• Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.

  Cancer discovery 20120701

• Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.

  British journal of pharmacology 20120601

• Novel small-molecular therapeutics for rheumatoid arthritis.

  Current opinion in rheumatology 20120501

• A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.

  Arthritis and rheumatism 20120401

• In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.

  Annals of the rheumatic diseases 20120401

• The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon.

  Annals of the rheumatic diseases 20120301

• EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer.

  PloS one 20120101

• Targeting JAK3 in kidney transplantation: current status and future options.

  Current opinion in organ transplantation 20111201

• Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium.

  The Journal of rheumatology 20111101

• IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.

  International immunology 20111101

• A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690,550) does not prolong QTc interval in healthy participants.

  Journal of clinical pharmacology 20110901

• Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.

  Arthritis care & research 20110801

• Current landscape for T-cell targeting in autoimmunity and transplantation.

  Immunotherapy 20110701

• Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

  Journal of immunology (Baltimore, Md. : 1950) 20110401

• Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.

  Journal of medicinal chemistry 20110113

• CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.

  Arthritis research & therapy 20110101

• Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production.

  BMC immunology 20110101

• Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

  Journal of medicinal chemistry 20101223

• Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients.

  Therapeutic drug monitoring 20101201

• Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile.

  Kidney international. Supplement 20100901

• Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.

  Best practice & research. Clinical rheumatology 20100801

• Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6.

  Journal of molecular biology 20100716

• Novel immunosuppressive agents in kidney transplantation.

  Clinical nephrology 20100501

• A receptor-independent, cell-based JAK activation assay for screening for JAK3-specific inhibitors.

  Journal of immunological methods 20100331

• Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients.

  Transplantation 20091027

• Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20090801

• The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

  Arthritis and rheumatism 20090701

• Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers.

  Journal of clinical pharmacology 20090401

• The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients.

  Transplantation 20090115

• Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).

  Journal of medicinal chemistry 20081225

• Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20080801

• The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.

  Cancer science 20080601

• The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia.

  European journal of pharmacology 20080317

• Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.

  Arthritis research & therapy 20080101

• Arthritis clinical trial results revealed.

  JAMA 20070103

• Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates.

  Transplantation 20051227

• Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts.

  Transplantation 20051115

• JAK protein kinase inhibitors.

  Drug news & perspectives 20050601

• Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates.

  Transplantation 20050415

• The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing.

  Journal of leukocyte biology 20041201

• JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.

  Trends in molecular medicine 20041101

• Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.

  Science (New York, N.Y.) 20031031